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The eukaryotic cell possesses specialized pathways to turn over and degrade redundant proteins and organelles. Each pathway
is unique and responsible for degradation of distinctive cytosolic material. The ubiquitin-proteasome system and autophagy
(chaperone-mediated, macro, micro and organelle specific) act synergistically to maintain proteostasis. Defects in this
equilibrium can be deleterious at cellular and organism level, giving rise to various disease states. Dysfunction of quality
control pathways are implicated in neurodegenerative diseases and appear particularly important in Parkinson’s disease and
the lysosomal storage disorders. Neurodegeneration resulting from impaired degradation of ubiquitinated proteins and
α-synuclein is often accompanied by mitochondrial dysfunction. Mitochondria have evolved to control a diverse number of
processes, including cellular energy production, calcium signalling and apoptosis, and like every other organelle within the
cell, they must be ‘recycled.’ Failure to do so is potentially lethal as these once indispensible organelles become destructive,
leaking reactive oxygen species and activating the intrinsic cell death pathway. This process is paramount in neurons which
have an absolute dependence on mitochondrial oxidative phosphorylation as they cannot up-regulate glycolysis. As such,
mitochondrial bioenergetic failure can underpin neural death and neurodegenerative disease. In this review, we discuss the
links between cellular quality control and neurodegenerative diseases associated with mitochondrial dysfunction, with
particular attention to the emerging links between Parkinson’s and Gaucher diseases in which defective quality control is a
defining factor.
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Introduction
Mitochondria are a critical component of the eukaryotic cell,
responsible for energy production in the form of ATP, haeme
and phospholipid synthesis and calcium buffering (Duchen,
2000). They are also responsible for activation of the intrinsic
cell death pathway and can induce apoptosis (Green and
Reed, 1998). Mitochondria are organelles enclosed by a
double membrane with inner and outer membranes that
maintain and separate two distinct aqueous compart-
ments, the inter-membrane space and the matrix. Reflecting
their bacterial evolutionary origin the mitochondria have
maintained their own genome with 13 respiratory chain
proteins, 2 rRNAs and 22 tRNAs encoded (Andersson et al.,
1998; Levinger et al., 2004). Correct mitochondrial function
requires a tight coordination between nuclear and mitochon-
drial encoded genes though various anterograde and retro-
grade signalling pathways (Ryan and Hoogenraad, 2007).
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The inner mitochondrial membrane houses the major
enzymatic system; the respiratory chain used to transduce
oxygen consumption to generate cellular energy in the form
of ATP (Mitchell, 1961; Mitchell and Moyle, 1967). The elec-
tron transport chain functions by oxidizing NADH and
FADH2 generated by the citric acid cycle and using these to
power the pumping of protons from the matrix into the inter
membrane space, generating a potential gradient across the
inner membrane (Rich, 2003). It is this potential difference
that drives the phosphorylation of ADP to ATP at complex V,
the F1Fo-ATP synthase. Mitochondria are the cell’s most effi-
cient way of producing energy earning the textbook appella-
tion – ‘the powerhouse of the cell’ (McBride et al., 2006;
Osellame et al., 2012). However, mitochondria are far more
complex than a simple cellular battery. In addition to the
traditional roles assigned to mitochondria, it is clear they also
participate in diverse process such as innate immunity (Seth
et al., 2005), cardiac and neuronal ischaemia reperfusion
(Schinzel et al., 2005; Ong et al., 2010) and ageing (Ross et al.,
2013). Hence, defective mitochondrial function will almost
inevitably be deleterious to cell and tissue functions threat-
ening the well-being of the entire organism. Impaired mito-
chondrial function has been associated with various disease
states in the CNS, including Leigh syndrome, Freidreich’s
ataxia and motor neuron, Alzheimer’s (AD), Huntington’s
(HD) and Parkinson’s diseases (PDs; Santorelli et al., 1993;
Mecocci et al., 1994; Panov et al., 2002; Valente et al., 2004).
Impaired mitochondrial function is particularly damaging in
highly energetic, polarized cells such as neurons (Park et al.,
2001).
Neurons have an absolute dependence on mitochondrial
oxidative phosphorylation for their ATP supply, with very
limited capacity for glycolysis (Herrero-Mendez et al., 2009;
Bolanos et al., 2010). Taking this into account, it is no surprise
that the correlation between defects in mitochondrial func-
tion and neurodegenerative disorders is relatively high
(Schapira et al., 1990a,b; Betarbet et al., 2000; Cui et al., 2006;
Lin and Beal, 2006). Many of these reports also specify defects
in cellular and mitochondrial quality control (Rubinsztein,
2006; Martinez-Vicente and Cuervo, 2007; Pan et al., 2008).
Dysfunctional mitochondria can be harmful to the cell as
complex I (CI; and to a lesser extent CIII) of the respiratory
chain generate damaging reactive oxygen species (ROS;
Chance et al., 1979; Liu et al., 2002). These may in turn cause
further damage to the respiratory chain, providing a destruc-
tive feedback cycle that can amplify the mitochondrial
damage, resulting in neuronal death. Thus, these organelles
need to be turned over by the cell’s quality control system,
and failure of this pathway is strongly associated with neu-
rodegenerative disease (Hara et al., 2006; Komatsu et al.,
2006; Levine and Kroemer, 2008; Narendra et al., 2008).
The main clearance pathway for organelle turnover in
cells is the autophagic pathway. Central to this pathway is the
lysosome, with its low pH and lytic enzymes. Until recently,
lysosomes were simply viewed as the organelle responsible for
cellular waste disposal. Compelling evidence suggests that
the biology of the lysosome extends far beyond the lytic
enzymes housed with the lumen (Cesen et al., 2012). They are
platforms for calcium signalling (Churchill et al., 2002;
Kilpatrick et al., 2013), important in trafficking organelles
involved in endocytosis (Chieregatti and Meldolesi, 2005)
and involved in nutrient sensing (Sancak et al., 2010). The
multifactorial role of lysosomes places them at the crossroads
of cellular homeostasis (Settembre et al., 2013). In autophagy,
once the lysosome is fused with the autophagosome, it
degrades engulfed organelles and proteins. Alterations in
autophagic rate have been implicated in the aforementioned
neurodegenerative disorders as well as many lysosomal
storage disorders (LSDs; Cuervo et al., 2004; Boland et al.,
2008; Settembre et al., 2008a; Osellame et al., 2013).
The LSDs are a group of rare inherited metabolic disor-
ders, which result from lysosomal dysfunction that stems
from mutations or deficiency of a single lysosomal enzyme.
Collectively, LSDs occur at a frequency of ∼1:10 000 with
Gaucher disease (GD) as the most prevalent of the group
(Meikle et al., 1999; Westbroek et al., 2011). GD is caused by
mutations in the glucocerebrosidase (GBA) gene and is associ-
ated with PD as it appears that similar underlying defects in
autophagy and mitochondrial dysfunction may link the neu-
rodegenerative aspect of these two disorders (Tayebi et al.,
2001; Sun and Grabowski, 2010; Westbroek et al., 2011;
Osellame et al., 2013). Mitochondrial dysfunction has also
been associated with other LSDs including mucolipidosis
(ML), Batten disease (BD) and multiple sulphatase deficiency
(MSD; Jennings et al., 2006; Settembre et al., 2008a; de
Pablo-Latorre et al., 2012). It seems that cellular quality
control is central to maintaining correct mitochondrial func-
tion and protecting from neurodegeneration in numerous
disease states (Lee et al., 2012).
Cellular quality control pathways
The eukaryotic cell is equipped with specific machinery to
turn over and degrade unwanted/dysfunctional material.
These include the ubiquitin-proteasome system (UPS) and the
autophagic pathways: chaperone-mediated (CMA), macro,
micro as well as organelle specific (pexophagy, reticulophagy,
ribophagy and mitophagy; Klionsky and Emr, 2000; Cuervo
et al., 2004; Dunn et al., 2005; Bernales et al., 2006; Kim et al.,
2007; Ron and Walter, 2007; Kraft et al., 2008). Each pathway
degrades a different type of substrate. The UPS is ultimately
responsible for degradation of proteins that are poly-
ubiquitinated on lysine 48 and generally have a short half-life
(Bence et al., 2001). CMA is a highly specialized form of
autophagy. In this pathway, chaperones, such as heat shock
cognate protein 70 (Hsc70), guide only certain misfolded
proteins (such as α-synuclein) to the lysosome (Cuervo et al.,
2004). Macroautophagy is the bulk cytosolic pathway for
relatively non-selective turnover of damaged/dysfunctional
organelles and ubiquitinated proteins (modified on lysine
63) with a long half-life (Levine and Klionsky, 2004).
Mitophagy is initiated by the damaged mitochondrion itself,
which is ultimately degraded by the macroautophagic
pathway (Lemasters et al., 1998; Narendra et al., 2008). While
each system possesses qualities that are unique, it is impera-
tive that they act in a cooperative manner to maintain
proteostasis.
Macroautophagy
Macroautophagy, commonly known as autophagy, is the
lysosomal-dependent degradation pathway. Autophagy is an
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essential process and primarily functions to remove damaged
and dysfunctional proteins and organelles from the cell.
The initial step of the autophagic pathway – the mem-
brane origins of the autophagosome – remains unclear. There
are various reports suggesting that the membrane compo-
nents could either be generated de novo or may arise from
other intracellular membrane structures, like that of the
endoplasmic reticulum (ER), or more recently reported, the
mitochondria (Axe et al., 2008; Hailey et al., 2010). Initiation
is enhanced by activation of Vps34 and its interaction with
Beclin1. This step can only proceed once the anti-apoptotic
protein Bcl-2 is phosphorylated and thus dissociated from
Beclin1, indicating interesting links between the autophagy
and apoptosis pathways (Xie and Klionsky, 2007; Funderburk
et al., 2010). The Atg family of proteins are required for the
maturation of the autophagosomal membrane. This stage of
the process involves several ubiquitin-like conjugation reac-
tions. The second step of the conjugation system involves
Atg8, known in mammalian systems as LC3 (microtubule-
associated protein 1A/1B-light chain 3). LC3 is present in two
forms depending on the progression of the pathway. In its
cytosolic form, it is known as LC3-I; however, when cova-
lently conjugated to phosphatidylethanolamine (PE; in a
reaction involving Atg 3 and 7) on the autophagosomal
membrane, it is known as LC3-II (Xie and Klionsky, 2007).
This form of the protein is present on both the elongating
membrane and the newly formed autophagosomes that have
engulfed damaged organelles and proteins (Figure 1). It
remains on the membrane until fusion with the lysosome.
This fusion of the autophagosome and the lysosome results in
formation of the lytic organelle, the autolysosome. This step
requires functional SNARE [SNAP (soluble NSF attachment
protein) receptor)] proteins and has an absolute dependence
on normal lysosomal function (Fader et al., 2009). The com-
bination of low pH and lytic enzymes from the lysosome and
damaged organelles/misfolded proteins from the autophago-
some ensure that engulfed material is degraded and the lib-
erated macromolecules recycled for use during cellular
starvation. The autophagy pathway is capable of degrading
either proteins with long half-lives or organelles. The cyto-
solic adaptor p62/sequestosome 1 (p62/SQSTM1) traffics
poly-ubiquitinated proteins to autophagosomes, possibly
via linkage with LC3 in preparation for degradation via
autophagy (Bjorkoy et al., 2005). Selection of organelles for
turnover via autophagy occurs at the organelle level with
most possessing specialized, specific pathways to mediate ini-
tiation of degradation.
Mitophagy
The cell possesses organelle-specific turnover pathways in
addition to the more general autophagy pathway. Mitochon-
drial specific degradation, termed mitophagy, requires the
coordination of cytosolic factors and signals on the outer
mitochondrial membrane (OMM). The process of mitophagy
is remarkably specific; by uncoupling a single mitochondrion
via photo-irradiation, this and only this mitochondrion will
be degraded (Kim and Lemasters, 2011). Further to this,
damaging the entire mitochondrial pool using an uncoupler
(carbonyl cyanide 3-chlorophenylhydrazone) promotes mito-
chondrial degradation while leaving other organelles intact
(Narendra et al., 2008).
The two key regulators of mitophagy are members of the
PARK family of genes, which associate with familial forms of
PD. These include mutations in PARK6, which encodes the
putative serine/threonine kinase PINK1 (PTEN-induced puta-
tive kinase protein 1) and PARK2 encoding the E3 ubiquitin
ligase Parkin (Kitada et al., 1998; Valente et al., 2004). Parkin
mutations account for a high proportion of patients with
familial PD, especially those whose onset is considered early
(i.e. before 25 years of age; Abbas et al., 1999; Lucking et al.,
2000; Abou-Sleiman et al., 2006). PINK1 encodes a 581 amino
acid protein, which contains an N-terminal mitochondrial
targeting signal and a transmembrane domain that anchors it
into the inner mitochondrial membrane (IMM), while the
sequence of PINK1 strongly suggests the presence of a
C-terminal kinase domain (Silvestri et al., 2005; West et al.,
2005). The structure of Parkin is slightly more complex than
that of PINK1. It contains an N-terminal ubiquitin-like
domain. The rest of the protein comprises varying RING
domains. In the remaining N-terminal domain, Parkin pos-
sesses three RING domains and an in-between domain
(Deshaies and Joazeiro, 2009). The C-terminus as a whole is
termed RING in-between-RING domain (Beasley et al., 2007).
Most importantly however, this region contains the E3 ubiq-
uitin ligase domain and the recently characterized HECT-like
domain. This HECT-like domain is suggested to be responsi-
ble for Parkin recruitment to mitochondria and thus activa-
tion of mitophagy (Lazarou et al., 2013).
PINK1 and Parkin function in the same pathway,
with PINK1 acting upstream of Parkin (Figure 1). In viable
mitochondria, PINK1 is imported in a membrane potential
(ΔΨm)-dependent manner (Jin et al., 2010). It normally
localizes to the IMM where it is almost immediately cleaved
by the rhomboid-like protein PARL (presenilins-associated
rhomboid-like protein; Jin et al., 2010; Deas et al., 2011;
Greene et al., 2012). Once cleaved, it is degraded by an
MG132-sensitive protease (Jin et al., 2010). These cleavage
steps are critical in normal cell homeostasis as they restrict
PINK1 expression. When mitochondria are damaged (and
ΔΨm is dissipated), PINK1 fails to import and accumulates on
the OMM where it remains trapped at the TOM complex,
recruiting Parkin to the OMM where it exerts its E3 ligase
activity (Lazarou et al., 2012). Ubiquitination of OMM pro-
teins such as Mfn1/2, VDAC1 and components of the TOM
complex (20, 40, 70) ensure that the mitochondrion is truly
marked for turnover (Gegg et al., 2010; Poole et al., 2010;
Chan et al., 2011). Ubiquitination of VDAC1 is suggested to
trigger recruitment of the autophagy adaptor p62/SQSTM1,
in a role similar to that it performs in the cytosol, where it
essentially ‘chaperones’ ubiquitinated proteins to the protea-
some, activating recruitment and conjugation of the phago-
phore, and ensuring encapsulation and eventual turnover of
the damaged mitochondrion (Geisler et al., 2010).
The manner in which Parkin ubiquitinates OMM proteins
has recently been identified. Although there do not appear to
be sequence motifs common to proteins ubiquitinated by
Parkin, it seems that the rationale for the modification of
proteins is actually very simple. Sole recruitment of Parkin to
the outer membrane and proximity to target proteins may be
all that is required for ubiquitination (Sarraf et al., 2013).
Supporting this, it seems that only the cytoplasmic face of the
outer membrane proteins are modified (Sarraf et al., 2013).
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Cellular quality control pathways. Quality control pathways revolve around the autophagy pathway. Expansion of the isolation membrane is
initiated by the Atg family of proteins. LC3-I is converted to LC3-II once conjugated to PE on the autophagosome membrane. Once damaged
organelles and proteins are engulfed, the autophagosome fuses with the lysosome to form the autolysosome, which facilitates the degradation
of the material. The UPS, CMA and mitophagy pathways degrade specific substrates. UPS, poly-ubiquitinated proteins; CMA, specific misfolded
proteins; mitophagy, damaged mitochondria.
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Perhaps Parkin ubiquitination is less selective than first
thought? Recently, an alternative Parkin receptor has been
proposed, adding another piece to an already complex
puzzle. Mitofusin 2 (Mfn2; an OMM GTPase primarily
responsible for mitochondrial fusion), is phosphorylated
by PINK1 and has been shown to be indispensible for
depolarization-induced Parkin translocation to mitochondria
in cardiomyocytes (Chen and Dorn, 2013). However, there is
most likely some redundancy in the recruitment system, as
Parkin still translocates to the OMM in Mfn2-depleted embry-
onic fibroblasts (Chan et al., 2011). Whether this specific
mechanism is of primary importance in the heart and a
secondary mechanism in other tissues remains to be seen.
Although a complex multi-step process, regulation of
mitophagy under the PINK1/Parkin (Mfn2?) system does
seem logical. However some doubts remain as to the physi-
ological relevance of this pathway. Although well character-
ized, experimental demonstration of this model pathway
relies on complete depolarization of the ΔΨm with prolonged
exposure to high doses of uncoupler. Whether an equivalent
process actually occurs in vivo and in disease states where
mitophagy is defective (i.e. PD and some LSDs) is not clear.
Chaperone-mediated autophagy (CMA)
CMA is one of the lysosomal pathways of proteolysis. It is
markedly different to conventional autophagy as no vesicular
transport is involved; instead, cytosolic proteins are recog-
nized and delivered to the lysosome by chaperones in a
molecule-by-molecule-dependent manner (Dice, 2007). In
this fashion, the mechanism of CMA is similar to that of
protein import into the mitochondria. Cytosolic proteins
with the KFERQ-like motif are recognized by the cognate
receptor chaperone Hsc70 (Chiang et al., 1989; Terlecky et al.,
1992). This motif and slight modifications of it are present in
30% of cytoplasmic proteins, thus CMA accounts for a sig-
nificant portion of the turnover of misfolded/damaged pro-
teins (Chiang and Dice, 1988). Included in this group are
mutant huntingtin and α-synuclein, associated with HD and
PD respectively. While it has been proposed that both
autophagy and the UPS degrade α-synuclein, impaired deg-
radation of mutant α-synuclein by CMA has been generally
implicated in neurodegeneration (McNaught et al., 2001;
Cuervo et al., 2004; Ebrahimi-Fakhari et al., 2011).
Under normal circumstances CMA is induced under star-
vation conditions with heat shock protein 40 (Hsp40) stimu-
lating Hsc70 activity, which then binds substrate proteins in
an ATP-dependent manner. Hsc70 (along with co-chaperones
hip, hop, bag-1, Hsp40 and 70) transport the cytosolic
protein to the membrane of the lysosome where they bind
to lysosome-associated membrane protein 2A (LAMP-2A;
Agarraberes and Dice, 2001; Figure 1). Like mitochondrial
protein import, these proteins must be unfolded prior to
transport into the lysosomal lumen and the chaperones are
vital for this process. The binding of Hsc70 and the substrate
to LAMP-2A monomers, triggers the assembly of LAMP-2A
multimers to form a translocation complex though which the
substrate can pass, although in an unfolded state. Lysosomal
heat shock cognate 70 (Ly-Hsc70), the lysosomal form of the
chaperone, is required to ‘pull’ the translocated protein
through the membrane receptor LAMP-2A (Agarraberes et al.,
1997). Post-translocation, these proteins are rapidly degraded
by lysosomal hydrolases. Binding and translocation to and
across LAMP-2A appear to be limiting factors in the causation
of PD; α-synuclein mutations in the KFERQ-like motif have
been shown to bind to LAMP-2A but fail to be translocated,
leaving them in an aggregated/misfolded state on the lyso-
some (Cuervo et al., 2004). As CMA degradation occurs
in a molecule-by-molecule fashion, binding of mutant
α-synuclein renders this process inactive as uptake/binding
and degradation of other CMA substrates is inhibited leading
to impaired proteostasis, which probably contributes to the
pathophysiology of PD and synucleinopathies.
Ubiquitin-proteasome system
The UPS prototypically recognizes specific protein substrates
that have been covalently modified by the addition of ubiq-
uitin (Ub), a small 76 amino acid polypeptide with poly-
ubiquitin marking the substrate for transportation to the
proteasome (Korolchuk et al., 2010). The UPS is responsible
for turnover of ubiquitinated misfolded/damaged proteins
with a short half-life. This is a highly catabolic process that
requires energy in the form of ATP, primarily generated from
mitochondria. The UPS is a highly regulated process under
the control of E1 (ubiquitin-activating enzyme), E2 (Ub con-
jugating enzyme) and E3 (ubiquitin ligase) enzymes, each
playing a specific role in post-translational modification of
target proteins (Deshaies and Joazeiro, 2009). The E1 and E2
class of enzymes activate the ubiquitin in an ATP-dependent
process while the E3 ligase performs the final step in trans-
ferring the activated ubiquitin to the ε-amino group of the
lysine residue in the target protein (Hershko et al., 1983;
Pickart and Eddins, 2004). Degradation of the targeted
protein by the UPS requires poly-ubiquitination at lysine 48
(Rodrigo-Brenni et al., 2010). These proteins are transported
by the cytosolic adaptor p62/SQSTM1 and various ubiquitin
receptor proteins, which function as ubiquitin-binding scaf-
fold proteins, binding aggregates in the cytosol (Elsasser and
Finley, 2005). As a key component of the ubiquitin system,
p62/SQSTM1 is a vital link between the UPS and autophagy,
and is itself ultimately degraded by autophagy (Seibenhener
et al., 2004; Korolchuk et al., 2009). It is a common compo-
nent of protein aggregates and Lewy bodies (LB) found in PD,
mutant huntingtin aggregates in HD and neurofibrillary
tangles in AD (Kuusisto et al., 2001; 2002; Nagaoka et al.,
2004; Bjorkoy et al., 2005).
The proteasome is a barrel-shaped proteolytic organelle
expressed throughout the cell. It consists of a central 20S
subunit and two 19S ‘lid’ units. The 20S subunit is considered
the proteolytic core of the complex, with the 19S units
serving as the protein-binding components (Dahlmann et al.,
1986; Lowe et al., 1995). The proteasome has relatively broad
activity divided into three main classes – chymotrypsin-
like, trypsin-like and peptidlyglutamyl–peptide hydrolysing
(Heinemeyer et al., 1997). The catalytic pore of the protea-
some is roughly 53 angstroms wide, although the entry point
can be as narrow as 13 angstroms, suggesting that the ubiq-
uitinated proteins must be at least partially unfolded to enter
the catalytic core (Nandi et al., 2006). This partial unfolding
appears to be one of the factors associated with the accumu-
lation of ubiquitinated proteins in neurodegenerative dis-
eases; highly aggregated proteins are poor proteasomal
substrates as they cannot be easily unfolded. As such, an
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impaired UPS is often suggested as an underlying molecular
mechanism in disease states such as PD, AD and HD.
Mitochondrial dysfunction in LSDs
Lysosomes were first described by Christian de Duve in 1949
and the name is derived from the Greek word lysis (to sepa-
rate) and soma (body) (De Duve et al., 1955). They range in
size from 0.1–1.2 μm with an acidic luminal pH of around
4.8, which is essential for lysosomal function (Mullins and
Bonifacino, 2001). They are membrane-bound organelles and
contain at least seven integral membrane proteins and about
50–60 soluble hydrolases (Futerman and van Meer, 2004).
Mutations in genes that encode these proteins can cause
LSDs, some of which are shown in Table 1. More than 40
LSDs have been described and these are classified and
grouped according to the nature of the accumulated sub-
strate. Most LSDs are inherited in an autosomal recessive
manner and present as infantile forms of the disease.
However, Fabry disease and Hunter syndrome (MPS II) are
X-linked and recessively inherited (Shachar et al., 2011).
Altered mitochondrial function has been reported in many
LSDs, namely, MSD (Settembre et al., 2008a; de Pablo-Latorre
et al., 2012), ML II, ML III (Otomo et al., 2009), ML IV
( Jennings et al., 2006), GM1-gangliosidosis (GM1; Takamura
et al., 2008; Sano et al., 2009), neuronal ceroid-lipofuscinoses
or BD (NCL3; Cao et al., 2006) and GD (Sun and Grabowski,
2010; Cleeter et al., 2013; Osellame et al., 2013).
Multiple sulphatase deficiency
MSD, also known as Austin disease and mucosulfatidosis, is a
rare LSD caused by mutations in the SUMF1 gene, resulting in
Table 1
Lysosomal storage disorders
Disease Gene (protein) Accumulated substrate
CNS
affected
QC
affected
Mitochondria
affected
Gaucher GBA (GBA/GCase) GBA + + +
Nieman-Pick type C NPC1/2 (Neiman-Pick C 1/2) Sphingolipids and
cholesterol
+ + −
Mucopolysaccharidosis
Type II (Hunter
syndrome)
I2S (iduronate-2-sulphatase) Heparan sulphate and
dermatan sulphate
+ + +
Type IIIA (Sanfilippo
syndrome)
SGSH (heparan N-sulphatase) Glycosaminoglycan
heparan sulphate
+ + +
Type IIIB (Sanfilippo
syndrome)
NAGLU (N-acetyl-α-D
glucosaminidase)
Heparan sulphate + − +
Multiple sulphatase
deficiency
SUMF1 (sulphatase-modifying
factor-1)
Sulphatides, sulphated
glycosaminoglycans,
sphingolipids and
steroid sulphates
+ + +
Fabry GLA (α-galactosidase) Globotriasylceremide − + +
Tay-Sachs (GM2
gangliosidosis/
hexosaminidase A
deficiency
HEXB (β-hexosaminidase) GM2 ganglioside + + −
Lipofuscinosis (NCLs)
Type I CLN1 (palmitoyl protein
thioesterase)
Lipodated thioesters and
lipofusin
+ − −
Type III (Batten) CLN3 (ceroid-lipofuscinosis
3/battenin)
Subunit c of the
mitochondrial ATP
synthase/complex V
+ + +
Pompe GAA (acid-α-glucosidase) Glycogen + + −
Mucolipidosis
Type II-II GNPTAB (N-acetylglucosamine-1-
phosphotransferase)
N-linked glycoproteins + − +
Type IV MCOLN1 (mucolipin 1) Phosphatidylcholine,
lysophosphatidylcholine,
phosphatidylethanolamine
+ + +
A selection of LSDs that harbour CNS abnormalities, quality control (QC) defects and/or mitochondrial dysfunction.
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an accumulation of sulphatides, sulphated glycosaminogly-
cans, sphingolipids and steroid sulphates (Austin, 1973;
Cosma et al., 2003; Dierks et al., 2003). Affected individuals
present with neurological deterioration, ichthyosis, skeletal
anomalies and organomegaly. There are three types of MSD,
differentiated according to age of onset – neonatal, late infan-
tile and juvenile, with neonatal being the most severe and
results in death in the first year of life (Dierks et al., 2003).
In murine models of MSD, defects in both autophagy and
mitophagy have been observed (Settembre et al., 2008a; de
Pablo-Latorre et al., 2012). Mitochondria in these models
were found to be fragmented with a reduced ΔΨm. Originally,
it was proposed that the inability to turn over these dys-
functional mitochondria was due to ineffective lysosome-
autophagosome fusion, as autophagosome number was
increased (Settembre et al., 2008a,b). However, it appears that
impaired Parkin-mediated ubiquitination of the OMM may
contribute to defective proteostasis (de Pablo-Latorre et al.,
2012). As well as a decreased ΔΨm, the mitochondrial network
was fragmented and ATP production was reduced, indicating
a generalized mitochondrial dysfunction. Parkin failed to
translocate to the OMM, and OMM proteins were only par-
tially ubiquitinated; thus, the mitochondria were not tagged
for degradation (de Pablo-Latorre et al., 2012). However, this
study by de Pablo-Latorre and colleagues described liver mito-
chondria; the same ‘mitochondrial priming’ (i.e. marking the
organelle for turnover) was not seen in the brain. Given the
progressive degenerative nature of MSD, it is unclear whether
there are similar mitophagy defects in the brain that may
have been masked by the nature of the experimental material
(whole brain) in this study. Perhaps this again suggests (like
Mfn2 as a potential redundant receptor in the heart) that the
regulation of the mitophagy pathway is tissue specific.
Mucolipidosis (ML)
ML is a collective name for the group of autosomal recessive
diseases in which the accumulated substrate is phospholipid
(Mancini et al., 2000; Mach, 2002). There are four types of
ML, types I–III involve the mis-targeting of lysosomal lipid
hydrolases, resulting in inefficient processing of endocytosed
lipids (Bach and Desnick, 1988; Bargal and Bach, 1989;
Slaugenhaupt, 2002). Type IV (ML IV), however, differs
slightly as it is linked to mutations in the proposed ion-
channel, mucolipin 1 (MCOLN1), a protein suggested to play
a role in lysosomal/endosome function (Bargal and Bach,
1989; Fares and Greenwald, 2001; LaPlante et al., 2004). Inter-
estingly, ML IV is often misdiagnosed as cerebral palsy; thus,
the reported incidence of 1:40 000 is thought to be conserva-
tive (Altarescu et al., 2002). The carrier rate among the Ash-
kenazi population is highly elevated in comparison to the
general population, with two founder mutations (c416-2 A >
G and C.1_788del) giving rise to a carrier rate of 1:90–1:100
(Bargal et al., 2001; Bach et al., 2005).
Fibroblasts from ML IV harbour dysfunctional mitochon-
dria. Mitochondria in type IV (and II, III) were fragmented
with a reduced ability to buffer Ca2+ ( Jennings et al., 2006).
This is problematic for neuronal cells as reduced calcium
uptake can render them particularly vulnerable to calcium-
mediated apoptosis (Duchen, 1999; Kruman and Mattson,
1999). And as such, ML IV cells were more susceptible to
stress-induced cell death (caspase 8 dependent; Jennings
et al., 2006). This suggests that impaired lysosomal function
affects the autophagic turnover of dysfunctional mitochon-
dria, which therefore show increased susceptibility to stress-
induced apoptosis.
GM1-gangliosidosis
GM1-gangliosidosis is a rare inherited disorder that is
generally characterized by progressive neurodegeneration
(Brunetti-Pierri and Scaglia, 2008). GM1-gangliosidoses are
caused by recessive mutants in the β-galactosidase gene
(Suzuki and Oshima, 1993). The protein β-galactosidase is a
lysosomal hydrolase that hydrolyses the terminal galactosyl
residues from GM1-ganglioside, glycosaminoglycans and gly-
coproteins (Okada and O’Brien, 1968). There are three clini-
cal subtypes of GM1-gangliosidosis, which are generally
classified by age of onset. Type I (infantile) presents most
frequently at birth or in early infancy with neurolipidosis
(neurodegeneration with cherry-red spots in the eye;
Brunetti-Pierri and Scaglia, 2008). Type II presents with a
viable clinical phenotype including neurodegeneration,
ataxia and seizures. Type II (adult) is classified as late age of
onset and presents with progressive dementia, Parkinsonism
and dystonia (Suzuki, 1991; Roze et al., 2005). Only patients
with type III GM1-gangliosidosis survive to adulthood.
The severity of the disease is related to the residual activ-
ity of the mutant β-galactosidase enzyme with the most
severe mutations resulting in little to no enzyme found at
lysosomes (Suzuki et al., 1978). Using knockout mouse
models of β-galactosidase, it has been suggested that
enhanced autophagy and mitochondrial dysfunction may be
responsible for some aspects of neurodegeneration in GM1-
gangliosidosis (Takamura et al., 2008; Sano et al., 2009). Both
LC3-II and Beclin1 levels were enhanced in the brain in
addition to activation of Akt-mammalian target of rapamycin
(mTOR) and Erk signalling pathways. At the organelle level,
increased activity of cytochrome c oxidase (CIV) was
observed in astrocytes as well as abnormal mitochondrial
morphology and a decrease in ΔΨm (Takamura et al., 2008).
Cellular dysfunction was attenuated by inhibiting auto-
phagy (with 3-methyl adenine), suggesting that overactiva-
tion of autophagy may play a role in the pathophysiology
of GM1-gangliosidosis (Takamura et al., 2008). Deregulated
calcium signalling has also been postulated to play a role
in GM1-gangliosidosis. As well as accumulating in lyso-
somes, GM1-ganglioside has been shown to associate with
glycophospholipid-enhanced microdomains of mitochon-
drial associated ER membranes (Sano et al., 2009). Here, it is
proposed to interact with the phosphorylated form of the
inositol triphosphate receptor, affecting the activity of the
receptor and resulting in perturbations in calcium uptake by
mitochondria, leading to organelle dysfunction (Sano et al.,
2009).
Batten disease (NCL type III)
Neuronal ceroid lipofuscinosis (NCL) or BD are recessively
inherited neurodegenerative disorders, characterized by lyso-
somal accumulation of subunit c of the ATP synthase within
neurons (Palmer et al., 1992). They are the leading cause of
neurodegeneration among children and are always fatal
(Wisniewski et al., 2001). Although rare, BD is found in all
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populations, it is however more prevalent in Finland where it
is thought to occur at a frequency of 1:10 000 (Santavuori,
1988). A founder mutation in the gene CLN3 (also known as
battenin) results in a 1.02 kb deletion of genomic DNA
(gDNA), resulting in deletions of exons 7 and 8 and the
flanking intronic gDNA. This causes multiple copies of stable
mutant CLN3 mRNA isoforms, all of which appear to be
non-functional. The wild-type CLN3 protein, localizes to the
lysosome/endosome. The protein is thought to be responsible
for assisting vesicular trafficking and in regulating pH and
amino acid transport. The accumulated material, subunit c of
the ATPase, normally resides within the IMM as a component
of the respiratory chain enzyme, complex V (CV; ATP syn-
thase), where it is responsible for the conversion of inorganic
phosphate and ADP to ATP, the cellular unit of energy (Rich,
2003). Although the underlying mechanism of the disease
has yet to be elucidated, alterations in mitochondrial func-
tion have been reported. Indeed, some reports regarding BD
suggest that mitochondrial metabolism is defective. Reduc-
tions in β-oxidation of palmitate have been shown in patient
fibroblasts, although it seems that respiratory chain function
in these cells is normal, suggesting that the selective turnover
of components of the mitochondria (namely, IMM) is defec-
tive (Hall et al., 1991; Palmer et al., 1992; Dawson et al.,
1996). A mouse knock-in model of the exon7/8 CLN3/
battenin deletion reveals defects in the autophagy pathway,
stemming from defects in autophagosome maturation (Cao
et al., 2006). Surprisingly, both subunit c and CLN3/battenin
were found to be enriched in the membrane of these delayed
autophagomes, hinting that the mitochondria may well be
involved in the origins of autophagosome formation (Cao
et al., 2006). The delayed progression of the autophagic
pathway has implications for organelle turnover in this
disease and although accumulation of subunit c of mitochon-
drial CV is specifically associated with BD, it appears that it
may be a secondary effect due to impaired autophagy in this
disease state.
Gaucher disease (GD)
GD is caused by recessive mutations in the GBA gene. The
GBA gene is located on chromosome 1q21 and contains 11
exons and 10 introns spanning a 7.6 Kb region. The func-
tional gene shares 96% exonic homology with a non-
processed pseudogene (16 Kb upstream) (Hruska et al., 2008).
It is the presence of this highly homologous pseudogene
along with six other genes in the region (including Metaxin1)
that can result in misalignments and chromosomal rear-
rangements which explain the relatively high amount of
recombinant alleles detected in GD (Hruska et al., 2008).
The protein product of GBA is glucerebrosidase (GCase)
and is responsible for the conversion of its substrate glucocer-
ebroside to glucose and ceramide (Brady et al., 1965). In the
disease state, deficiency of the enzyme results in accumula-
tion of toxic substrate within the lysosome. Although classi-
fied as a pan-ethnic disorder, prevalence varies depending on
population bias. In the general population occurrence is esti-
mated as 1:40 000; however, among Ashkenazi Jews, the
prevalence is thought to be as high as 1:900 (Zimran et al.,
1991; Aharon-Peretz et al., 2004). Classed as an in-born error
of metabolism, GD can be further classified into three types
based on age of onset and neurological involvement
(Grabowski, 2008). Type I (OMIM#230800) is the most
common and is defined by a lack of neurological features.
Type II (OMIM#230900) presents very early in life and is
classed as acute infantile neuronopathic GD. Type III
(OMIM#2301000) also presents with neurological involve-
ment but has a more chronic presentation. In many cases of
GD, the relationship between genotype and phenotype is
obscure and often does not correlate with enzyme activity,
making it very difficult to classify definitively (Grabowski,
2008). In addition, all types of GD present very differently in
the clinic and it has been reported than even affected siblings
with the same type of GD will present differently. Type 1, the
mildest form, presents with skeletal abnormalities and
enlarged liver (hepatomegaly) and/or spleen (splenomegaly)
among others (Grabowski, 2008). Type II presents with
hepatosplenomegaly, joint pain and CNS involvement –
seizures and mental retardation (Grabowski, 2008). The vis-
ceral symptoms of type I GD are currently treatable with
enzyme replacement therapy such as imiglucerase and vela-
glucerase; however, these enzymes do not cross the blood–
brain barrier and are thus not effective for types II and III
(Zimran et al., 2013).
The molecular mechanism underlying the pathology of
GD is poorly defined. Although the primary defect appears to
be lysosomal, the effects at cellular and organism level are
only beginning to be considered as the links between GD and
PD come to light (Sidransky, 2005; Dehay et al., 2010;
Mazzulli et al., 2011; Sidransky and Lopez, 2012; Cleeter
et al., 2013; Dehay et al., 2013; Osellame et al., 2013).
Links between GD and PD
PD is a progressive age-related neurodegenerative disorder
affecting 1% of the world’s population over the age of 65
(DePaolo et al., 2009). Physical symptoms include bradykin-
esia, tremors at rest, postural instability and rigidity. The
neuropathology is marked by the degeneration of dopamin-
ergic neurons in the substantia nigra pars compacta (SN) and
accumulation of α-synuclein positive LB within neurites.
Although the molecular mechanism of PD remains
unclear, much of the current understanding has been gained
by identification of distinct loci at which pathogenic muta-
tions are associated with Parkinsonism (Table 2). Of these,
mutations in GBA are numerically identified as the highest
known genetic risk factor for PD (Neudorfer et al., 1996;
Neumann et al., 2009; Lesage et al., 2011). Parkinsonism is
an established feature of GD and the pathological and neuro-
logical symptoms displayed by GD patients share many
features of PD. Several large multi-centre genome wide asso-
ciation studies have reported high incidences of GBA muta-
tions in sporadic PD (Sidransky, 2005; Mata et al., 2008; Mitsui
et al., 2009; Sidransky et al., 2009a,b; Sidransky and Lopez,
2012). Post-mortem analysis of PD patient brains with GBA
mutations revealed extensive GCase deficiency in the brain
with the SN most affected (Gegg et al., 2012). In addition,
involvement of an α-synuclein feedback loop in GD and
synucleinopathies suggests that accumulating oligomeric
α-synuclein inhibits the activity of endogenous wild-type
GCase in idiopathic PD brains, contributing to the progres-
sion of sporadic PD and synucleinopathies (Mazzulli et al.,
2011; Gegg et al., 2012; Manzoni and Lewis, 2013). This
mechanism appears to be similar to that of a self-propagating
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prion-like disease; where α-synuclein and GCase provide the
basis for a destructive feedback loop. Pharmacological inhibi-
tion of GCase by a specific inhibitor (conduritol-β-epoxide)
mimics the in vivo disease state. Chemical inhibition in the
neuronal-like SH-SY5Y cells also led to α-synuclein accumu-
lation. The mitochondrial pool is also affected resulting in
decreased ADP phosphorylation and reduced ΔΨm (Cleeter
et al., 2013). These studies suggest that decreased GCase activ-
ity, similar to that observed with pathogenic mutations of GD,
is the prime cause of the pathology associated with GD. Close
to 300 unique mutations of GBA have been reported to be
associated with GD, two of the most prevalent being L444P
and N370S, with the latter found in >98% of Jewish patients
and about half of non-Jewish patients (Beutler and Gelbart,
1993; Beutler et al., 1993; Hruska et al., 2008). These and other
mutations have been reported to cause defects of GCase traf-
ficking, with the mutated protein trapped in the ER, triggering
the unfolded protein response and undergoing ER-associated
degradation via the proteasome (Aharon-Peretz et al., 2004;
Wong et al., 2004; Gegg et al., 2012). As a result, very little
mutated GCase may actually be localized to the lysosome.
Either theory is enticing (self-propagating feedback loop or
ER-mediated degradation) as they present potential therapeu-
tic options for increasing GCase targeting to the lysosome.
Abundantly clear however is the absolute requirement for
active GCase in clearance of proteins such as α-synuclein and
maintaining proteostasis. Complete depletion of GCase in a
type II neuronopathic GD mouse model results in a global
decrease in quality control mechanisms in neurons (not just
CMA of α-synuclein). In this system, knockout (KO) of GCase
in primary neurons and astrocytes caused defects in the
autophagy pathway with reductions in LC3-I/II and Atg5/12
levels, suggesting the presence of a negative feedback loop
upstream of lysosomal involvement (Osellame et al., 2013).
Defective autophagy impinges on the UPS with increases in
ubiquitinated proteins, p62/SQSTM1 aggregates as well as α-
synuclein deposits in the midbrain. Defective mitochondrial
quality control is associated with mutations in the PARK
family of genes and can cause familial PD, yet very little is
known about the mitochondrial involvement in GD. It was
shown that as a result of defective quality control mecha-
nisms dysfunctional mitochondria in type II GD do not
recruit the E3 ubiquitin ligase Parkin, and are not flagged for
turnover and accumulate. GCase KO cells showed reduced
mitochondrial CI, CII/III activity and reduced ΔΨm. Similar to
that of PINK1 knock-down in neurons, mitochondrial mem-
brane potential is maintained by ATP hydrolysis by the F1Fo-
ATP synthase in type II GD neurons and astrocytes – the
mitochondria are no longer serving as sources of energy but
rather as ATP consumers (Gandhi et al., 2009; Osellame et al.,
2013). This coincides with mitochondrial fragmentation due
to increased OPA1 processing. Interestingly, loss of ΔΨm can
be attenuated by the mitochondrial targeted antioxidant
MitoQ10 (a ROS scavenger) suggesting that damage is medi-
ated by ROS generation from CI (James et al., 2004; Murphy
and Smith, 2007; Osellame et al., 2013). Treatment with
MitoQ10 did not restore defects in the autophagy pathway,
confirming that the primary lysosomal defect affects cellular
quality control (Osellame et al., 2013). Taken together, these
findings suggest that cellular dysfunction observed in GD,
like that of PD, is a consequence of defects in autophagy/
mitophagy pathways, resulting in failed clearance of
damaged mitochondria.
The bigger picture: mechanistic links
between LSDs and neurodegeneration
There appears to be a strong clinical association between
these two classes of disease. As the lysosome is central to the
Table 2
Parkinson’s disease associated genes
Locus Gene Function Clinical presentation
PARK1/4 α-synuclein Suggested involvement in synaptic function Parkinsonism, dementia with LB
PARK2 Parkin E3 ubiquitin ligase Early onset Parkinsonism
PARK5 UCHL1 Deubiquitinating enzyme Late onset Parkinsonism
PARK6 PINK1 Involved in sensing mitochondrial oxidative/stress.
Putative kinase activity
Early onset Parkinsonism, very rarely associated
with LB
PARK7 DJ-1 Involved in oxidative stress response Early onset Parkinsonism
PARK8 LRRK2 PK Late onset Parkinsonism, with LB
PARK9 ATP13A2 Encodes a lysosomal P-type ATPase. Exact
function unknown
Early onset Parkinsonism with Kufer-Rakeb
syndrome
PARK13 Htra2/Omi Serine protease Early onset Parkinsonism
PARK15 FBXO7 F-box protein, component of ubiquitin ligase
complex
Early onset Parkinsonism with Pallido-pyramidal
syndrome
GAUCHER GBA Lysosomal enzyme involved in glycolipid
metabolism
GD, late onset Parkinsonism with LB
ATP13A2, ATPase type 13A2; FBXO7, F-box protein 7; Htra2/Omi, high-temperature requirement protein A2/serine protease 25; LRRK2,
leucine-rich repeat kinase 2; UCHL1, ubiquitin carboxyl-terminal hydrolase L1.
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autophagy process, it is not unreasonable to assume this
pathway is integral in protecting against neurodegeneration
(Xilouri and Stefanis, 2011). Many of the products accumu-
lated in LSDs coincide with α-synuclein aggregation and the
presence of LB, thus it has been suggested that LSDs could be
classified as ‘autophagy disorders’ (Settembre et al., 2008b).
This may be the case with GD associated with PD. Accumu-
lation of α-synuclein and dysfunctional mitochondria, which
under normal cell homeostasis, should be turned over by
CMA/autophagy and mitophagy/autophagy, respectively,
suggests this may be the case. In addition, the UPS has also
been implicated in both disease states (McNaught et al., 2001;
Ross and Pickart, 2004; Ron and Horowitz, 2005). Taken
together, global defects in all aspects of cellular quality
control link the neurodegeneration seen in both PD and
LSDs. Although an overly simplistic view, up-regulation of
autophagy in diseases such PD and GD may alleviate some of
the clinical and pathological symptoms (Rubinsztein et al.,
2007; Fleming et al., 2011; Santos et al., 2011). However,
pharmacological treatment with drugs such as rapamycin,
which inhibits mTOR and thus induces autophagy, will result
in undesirable off-target effects especially when required for
chronic treatment (Rubinsztein et al., 2007). Lentiviral deliv-
ery of Beclin-1 may be a more effective option to ameliorate
autophagy and has been shown to reduce α-synuclein accu-
mulation in vivo (Spencer et al., 2009). Another option for
monogenic disorders may be intervention by gene therapy;
reintroducing a functional form of the gene via viral trans-
duction (Enquist et al., 2006; Rahim et al., 2009). As many of
the diseases discussed here cause rather severe neurodegen-
eration in infancy, both pharmacological and gene therapy
treatments would need to be applied in an early therapeutic
window (Waddington et al., 2005). As the intricate nature of
quality control pathways, the downstream effect on mito-
chondria and the neurodegeneration that follows is begin-
ning to come to light, the interplay between these may
present excellent therapeutic targets for clinical intervention.
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